Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908426 · ClinicalTrials.gov registry record · Phase 3
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
A Phase 3 study, sponsored by Exelixis.
- Completed
- Registry status
- Phase 3
- Development phase
- 707
- Enrollment target
NCT01908426 is a Phase 3 study that has completed, run by Exelixis. The registered enrollment target is 707 participants.
The verdict
NCT01908426, a Phase 3 study, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 707 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Interventions
- DRUG Cabozantinib tablets
- DRUG Placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 707 participants |
| Start Date | 2013-09-26 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908426
The ClinicalTrials.gov registry entry for NCT01908426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 707 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib tablets is the first listed.
NCT01908426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908426 about?
NCT01908426 is a clinical study titled "Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib". The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
What is the current status of trial NCT01908426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 707 participants. The study started on 2013-09-26. Estimated completion is 2021-01-12.
What interventions are being tested in trial NCT01908426?
The interventions under investigation include: Cabozantinib tablets (DRUG), Placebo tablets (DRUG).
Who is sponsoring clinical trial NCT01908426?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.